ANNX
USDAnnexon Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$2.660
Kõrge
$2.670
Madal
$2.510
Maht
1.85M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
276.5M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
1.80M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical
HC Wainwright & Co. Maintains Buy on Annexon, Lowers Price Target to $14
HC Wainwright & Co. analyst Andrew Fein maintains Annexon with a Buy and lowers the price target from $20 to $14.
Seotud aktsiad
BOXL
Boxlight Corporation
HBANM
Huntington Bancshares Incorporated Depositary Shares each representing a 1/1000th interest in a share of Huntington Series I Preferred Stock
ERC
Allspring Multi-Sector Income Fund
SNDX
Syndax Pharmaceuticals Inc.
ENJ
Entergy New Orleans LLC First Mortgage Bonds 5.0% Series due December 1 2052
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.